Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score,Arthritis & Rheumatology

当前位置： X-MOL 学术 › Arthritis Rheumatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
Arthritis & Rheumatology ( IF 13.3 ) Pub Date : 2021-09-12 , DOI: 10.1002/art.41965
Masataka Kuwana ₁ , Yannick Allanore ₂ , Christopher P Denton ₃ , Jörg H W Distler ₄ , Virginia Steen ₅ , Dinesh Khanna ₆ , Marco Matucci-Cerinic ₇ , Maureen D Mayes ₈ , Elizabeth R Volkmann ₉ , Corinna Miede ₁₀ , Martina Gahlemann ₁₁ , Manuel Quaresma ₁₂ , Margarida Alves ₁₂ , Oliver Distler ₁₃

Affiliation

Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Descartes University, AP-HP, and Cochin Hospital, Paris, France.
University College London Division of Medicine, London, UK.
University of Erlangen-Nuremberg, Erlangen, Germany.
Georgetown University, Washington, DC, USA.
University of Michigan, Ann Arbor.
University of Florence, Florence, Italy.
University of Texas McGovern Medical School, Houston.
University of California, Los Angeles.
mainanalytics, Sulzbach, Germany.
Boehringer Ingelheim, Basel, Switzerland.
Boehringer Ingelheim International, Ingelheim, Germany.
University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Using data from the SENSCIS trial, these analyses were undertaken to assess the effects of nintedanib versus placebo in subgroups of patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD), based on characteristics previously identified as being associated with the progression of SSc-ILD.

中文翻译：

尼达尼布治疗系统性硬化症相关间质性肺疾病：通过自身抗体状态和改良 Rodnan 皮肤厚度评分进行的亚组分析

使用来自 SENSCIS 试验的数据，根据先前确定与 SSc 进展相关的特征，进行这些分析以评估尼达尼布与安慰剂对系统性硬化症相关间质性肺病 (SSc-ILD) 患者亚组的影响-ILD。

更新日期：2021-09-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>